Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.

about

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.

Item

http://www.wikidata.org/entity/Q40160990

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Economic Evaluation of Tobramy ...... Patients with Cystic Fibrosis.

@en

type

Item

label

Economic Evaluation of Tobramy ...... Patients with Cystic Fibrosis.

@en

prefLabel

Economic Evaluation of Tobramy ...... Patients with Cystic Fibrosis.

@en

P1476

Economic Evaluation of Tobramy ...... Patients with Cystic Fibrosis.

@en

P2093

Laurie Debonnett

http://www.w3.org/2001/XMLSchema#string

Praveen Gunda

http://www.w3.org/2001/XMLSchema#string

Srilekha Panguluri

http://www.w3.org/2001/XMLSchema#string

P2860

Cost of care for cystic fibrosis: an investigation of cost determinants using national registry data.

Adherence with tobramycin inhaled solution and health care utilization.

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial.

Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Gender differences in outcomes of patients with cystic fibrosis

Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.

Improving rate of decline of FEV1 in young adults with cystic fibrosis.

P304

795-805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-017-0537-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kamal Hamed

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28643178

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

P932

5509782

http://www.w3.org/2001/XMLSchema#string